Semprus BioSciences to develop surface-modified endotracheal tube

Published on November 9, 2012 at 5:16 AM · No Comments

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that Semprus BioSciences, a wholly owned subsidiary of Teleflex Incorporated, has been awarded the initial phase of a $2.3 million research grant from the U.S. Army's Telemedicine and Advanced Technology Research Center (TATRC), located at Fort Detrick, MD. The award will support research and development of a surface-modified endotracheal tube that combines the Semprus SustainTechnology with the delivery of antimicrobials.

The research will be conducted at Semprus' facilities in Cambridge, MA, in conjunction with U.S. Army Institute for Surgical Research (USAISR) at Fort Sam Houston in San Antonio, TX. This award builds upon an initial $1 million TATRC grant awarded to Semprus BioSciences in 2011 to develop the world's first orthopedic devices designed to reduce biofilm formation.

"We are pleased to be working with the U.S. Army to help resolve a most critical issue affecting our wounded men and women in combat," said Benson Smith, Chairman, President and CEO of Teleflex. "This award was catalyzed by the U.S. Army's positive review of data from our prior award, and we are equally hopeful that this collaboration will yield greatly improved clinical outcomes for soldiers, as well as substantial cost savings to the U.S. military and civilian health care systems."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment